SCHEMBL18378752

SCHEMBL18378752

Cc1cccc2c(=O)n(C(C)C)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.46
CYP2A6 P11509 2/20 0.46
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HIF1A Q16665 1/20 0.38
EPAS1 Q99814 1/20 0.38
BRD4 O60885 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 3/20 0.36
P2RX7 Q99572 3/20 0.36
EZH2 Q15910 1/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 2/20 0.34
MAPT P10636 1/20 0.34
PABPC1 P11940 1/20 0.34
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18378820 0.84 CYP1A2 (0.45) CYP1A2CYP2A6HTR2AHTR2CHIF1A
SCHEMBL13114613 0.82 P2RX7 (0.53) CYP1A2CYP2A6HTR2AHTR2CHIF1A
SCHEMBL17577837 0.82 P2RX7 (0.53) CYP1A2CYP2A6HTR2AHTR2CHIF1A
SCHEMBL12668520 0.81 CYP1A2 (0.42) CYP1A2CYP2A6HTR2AHTR2CBRD4
SCHEMBL12668525 0.81 P2RX7 (0.45) CYP1A2CYP2A6HTR2AHTR2CHIF1A
SCHEMBL12668523 0.81 P2RX7 (0.45) CYP1A2CYP2A6HTR2AHTR2CHIF1A
SCHEMBL18368383 0.81 TSHR (0.36) CYP1A2HTR2CHIF1ASMN1; SMN2TSHR
SCHEMBL30349861 0.81 PARP1 (0.47) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL8230313 0.80 P2RX7 (0.54) CYP1A2CYP2A6HTR2AHTR2CHIF1A
SCHEMBL18379277 0.79 TDP1 (0.39) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938292-B2 Quinoline derivatives as SMO inhibitors GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-10 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-06-01 US disclosed
US-20170008905-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2017-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152240-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS CYP1A2 4427/4885CYP2A6 3831/4885HTR2A 2432/4885
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH CYP1A2 2991/4885CYP2A6 3189/4885HTR2A 1258/4885
US-20170008905-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS CYP1A2 4427/4885CYP2A6 3831/4885HTR2A 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.